PLX

Protalix Biotherapeutics Stock Analysis

AI Rating

Great
  • Quality8/10
  • Growth↑ 8/10
  • Value↑ 5/10
Protalix Biotherapeutics sales and earnings growth
PLX Growth
Good
  • Revenue Y/Y↑ 23.78%
  • EPS Y/Y↑ 280.00%
  • FCF Y/Y↑ 933.68%
Protalix Biotherapeutics gross and profit margin trends
PLX Profitability
Great
  • Gross margin ↑ 70.00%
  • EPS margin↑ 20.10%
  • ROIC 5Y↑ 14.99%
Protalix Biotherapeutics net debt vs free cash flow
PLX Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 13.5

Protalix Biotherapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks